Researchers Characterize New PLK4 Inhibitors for Cancer
The study identifies two potential inhibitors that show efficacy in specific tumor models with wild-type TP53.
Updated on Oct. 31, 2026 in Cancer
Live Poll
Do you trust that new lab research into cancer treatments will lead to real-world patient benefits?
Scientists have characterized two PLK4 inhibitors, EXEL-0667 and EXEL-1855, which regulate centriole biogenesis in cancer cells. These compounds demonstrate therapeutic potential in near-euploid tumor models that maintain wild-type TP53 status.
Why it matters
Identifying inhibitors that target PLK4 provides a potential new pathway for treating tumors beyond those with TRIM37 amplification. This research suggests that genome status and TP53 expression are critical factors in determining treatment sensitivity.
Researchers characterized two PLK4 inhibitors, EXEL-0667 and EXEL-1855, through in vitro cell viability assays and in vivo mouse xenograft studies. These findings suggest the drugs are effective in near-euploid tumor models with wild-type TP53.
The players
EXEL-0667
This is one of two newly characterized PLK4 inhibitors studied for its ability to regulate centriole biogenesis.
EXEL-1855
This is a PLK4 inhibitor that demonstrated in vivo efficacy in near-euploid tumor models with wild-type TP53.
The details
The research team utilized immunofluorescence to observe that partial PLK4 inhibition causes centrosome amplification in target cells. Findings indicate that high levels of TRIM37 sensitize cells to this inhibition, allowing for precise targeting of specific tumor genomes.
Timeline
The research findings were published on October 31, 2026.
The Big Picture
This study utilizes TCGA datasets to validate predictive biomarkers for tumor sensitivity to PLK4 inhibition. By anchoring the analysis in this genomic data, the research clarifies how TP53 wild-type status correlates with potential treatment response.
While these findings are limited to preclinical models, they offer a foundation for developing therapies that target specific tumor genetic profiles. Patients may eventually see these markers used to determine eligibility for personalized oncology treatments.
The takeaway
The successful targeting of PLK4 in near-euploid models suggests that genetic screening could soon play a larger role in predicting chemotherapy outcomes. Future therapeutic strategies may prioritize tumors based on TP53 status rather than just mutation presence.
Further reading
Learn more about the latest research in Cancer.
More information
Read the full peer-reviewed research article published in the scientific journal.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust that new lab research into cancer treatments will lead to real-world patient benefits?
